Clinical Scorecard: The immune profile of mobilized peripheral blood stem cells as a predictor of long-term outcomes and therapy-related myeloid neoplasms in multiple myeloma patients receiving autologous stem cell transplantation

At a Glance

Key Highlights

• 2–4% of MM patients develop therapy-related myeloid neoplasms (t-MN) post-ASCT, associated with poor survival.
• Immunosuppressive tumor microenvironment with T-cell exhaustion and immune senescence correlates with poor outcomes and relapse.
• Immune composition of mobilized PBSC grafts predicts post-ASCT relapse and t-MN development.

Guideline-Based Recommendations

Diagnosis

• Use 2016 WHO criteria to define therapy-related myeloid neoplasms (t-MN).
• Risk stratify MM patients using the revised international staging system (R-ISS).
• Assess hematologic response and engraftment syndrome per internationally accepted criteria.

Management

• Incorporate ASCT and maintenance therapy as backbone treatment for MM.
• Consider immune-based therapies and immunomodulation to improve long-term outcomes.
• Monitor for development of t-MN, especially in patients receiving novel therapies like CAR-T.

Monitoring & Follow-up

• Evaluate immune reconstitution post-ASCT focusing on immune effector cells and exhaustion markers.
• Monitor duration of remission post-ASCT (<24 months without maintenance or <48 months with maintenance indicates short remission).
• Use mass cytometry or equivalent immune profiling techniques to assess PBSC immune composition pre-transplant.

Risks

• High risk of relapse due to permissive immunosuppressive tumor microenvironment.
• Development of t-MN linked to TP53 mutations and immunosuppressed milieu.
• Potential increased incidence of t-MN following CAR-T therapy (10–20%).

Patient & Prescribing Data

Multiple myeloma patients undergoing ASCT with available cryopreserved PBSC products

Pre-existing immune abnormalities in mobilized PBSC grafts may predict early relapse and t-MN development, guiding personalized risk stratification and management.

Clinical Best Practices

• Perform immune profiling of mobilized PBSC grafts to identify high-risk patients prior to ASCT.
• Implement standardized cryopreservation and processing protocols for PBSC to ensure reliable immune analyses.
• Use validated antibody panels and mass cytometry for detailed immune cell subset characterization.
• Integrate immune reconstitution monitoring into post-ASCT follow-up to guide immunomodulatory interventions.
• Consider the impact of immune senescence and exhaustion in therapeutic decision-making.

References

• Multiple myeloma treatment and ASCT outcomes
• Therapy-related myeloid neoplasms and TP53 mutations
• Immune tumor microenvironment in MM
• Mass cytometry methodology for immune profiling
• 2016 WHO classification of myeloid neoplasms